"10.1371_journal.pone.0144900","plos one","2015-12-15T00:00:00Z","Dario Sorrentino; Marco Marino; Themistocles Dassopoulos; Dimitra Zarifi; Tiziana Del Bianco","IBD Center, Division of Gastroenterology, Virginia Tech-Carilion School of Medicine, Roanoke, Virginia, United States of America; Department of Clinical and Experimental Medical Sciences, University of Udine School of Medicine, Udine, Italy; Baylor Center for IBD, Baylor University Medical Center, Dallas, Texas, United States of America","Performed the experiments: DS MM DZ TDB. Analyzed the data: DS TD. Contributed reagents/materials/analysis tools: MM DZ TDB. Wrote the paper: DS TD.","D Sorrentino was a consultant for Janssen, Centocor, AbbVie, MSD, Hoffmann-LaRoche, Giuliani, TechLab, Schering-Plough, and Ferring. Prometheus Laboratories Inc, (San Diego CA) performed the tests for infliximab concentration, antibodies to infliximab and HS-CRP. The other authors have no conflicts of interest to disclose. No writing assistance was utilized in the production of this manuscript. There are no patents, products in development or marketed products to declare. This did not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","12","Dario Sorrentino","DS",5,TRUE,NA,4,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
